BioLineRx Ltd. (TLV:BLRX)

BioLineRx Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	1.18	28.94	4.8	-	-
Revenue Growth (YoY)	-95.92%	502.92%	-	-	-
Cost of Revenue	0.23	9.26	3.69	-	-
Gross Profit	0.95	19.68	1.11	-	-
Selling, General & Admin	3.14	29.68	31.58	11.53	5.31
Research & Development	8.09	9.15	12.52	17.63	19.47
Operating Expenses	11.24	38.83	44.1	29.16	24.78
Operating Income	-10.29	-19.15	-42.99	-29.16	-24.78
Interest Expense	-1.25	-9.07	-2.14	-1.79	-0.98
Interest & Investment Income	1.12	1.82	2.01	0.69	0.28
Currency Exchange Gain (Loss)	0.34	0.05	0.06	-0.35	0.28
Other Non Operating Income (Expenses)	8.05	18.39	-10.84	5.64	-1.85
EBT Excluding Unusual Items	-2.03	-7.97	-53.91	-24.95	-27.05
Asset Writedown	-	-1.26	-6.7	-	-
Pretax Income	-2.03	-9.22	-60.61	-24.95	-27.05
Earnings From Continuing Operations	-2.03	-9.22	-60.61	-24.95	-27.05
Minority Interest in Earnings	0.85	-	-	-	-
Net Income	-1.18	-9.22	-60.61	-24.95	-27.05
Net Income to Common	-1.18	-9.22	-60.61	-24.95	-27.05
Shares Outstanding (Basic)	2,465	1,198	963	774	663
Shares Outstanding (Diluted)	2,465	1,198	963	774	663
Shares Change (YoY)	105.76%	24.37%	24.47%	16.75%	162.19%
EPS (Basic)	-0.00	-0.01	-0.06	-0.03	-0.04
EPS (Diluted)	-0.00	-0.01	-0.06	-0.03	-0.04
Free Cash Flow	-8.1	-43.93	-22.72	-26.37	-23.67
Free Cash Flow Per Share	-0.00	-0.04	-0.02	-0.03	-0.04
Gross Margin	80.51%	67.99%	23.08%	-	-
Operating Margin	-871.78%	-66.18%	-895.65%	-	-
Profit Margin	-99.58%	-31.86%	-1262.79%	-	-
Free Cash Flow Margin	-686.36%	-151.78%	-473.42%	-	-
EBITDA	-10.06	-15.16	-41.61	-28.5	-24.07
EBITDA Margin	-	-52.38%	-	-	-
D&A For EBITDA	0.23	3.99	1.38	0.65	0.7
EBIT	-10.29	-19.15	-42.99	-29.16	-24.78
EBIT Margin	-	-66.18%	-	-	-
Revenue as Reported	1.18	28.94	4.8	-	-

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.